Status:
COMPLETED
Assessment of Patient-reported Goal Attainment in the Treatment of Female Overactive Bladder
Lead Sponsor:
Samsung Medical Center
Collaborating Sponsors:
Pfizer
Conditions:
Overactive Bladder
Eligibility:
FEMALE
18-80 years
Phase:
PHASE4
Brief Summary
For many years, antimuscarinics have been first-line pharmacological treatment for OAB. A recent meta-analysis of randomised, controlled trials on antimuscarinic treatment of OAB concluded that the dr...
Detailed Description
1. Objectives 1. Primary objective: To explore the "Patient-reported Goal Attainment (PGA)" after 12 weeks of treatment with tolterodine extended-release (ER) 4mg in female overactive bladder (OAB...
Eligibility Criteria
Inclusion
- Female aged ≥ 18 and ≤ 80 years
- Symptoms of OAB as verified by the screening 3 day micturition diary, defined by:
- Mean urinary frequency ≥8 times/24 hours Mean number of urgency episodes ≥ 2 episode/24 hours
- Symptoms of OAB for ≥ 3 months.
- Ability and willingness to correctly complete the micturition diary and questionnaire
- Capable of understanding and having signed the informed consent form after full discussion of the research nature of the treatment and its risks and benefits
Exclusion
- Subjects with stress incontinence or mixed stress/urge incontinence where stress incontinence is the predominant component based on prior history.
- Significant hepatic or renal disease, defined as having twice the upper limit of the reference range for serum concentrations of aspartate amino- transferase (AST \[SGOT\]), alanine aminotransferase (ALT \[SGPT\]), alkaline phosphatase or creatinine.
- Any condition that is a contraindication for anticholinergic treatment, including uncontrolled narrow-angled glaucoma, urinary retention or gastric retention
- Symptomatic acute urinary tract infection (UTI) during the run-in period
- Recurrent UTI defined as having been treated for symptomatic UTI \> 4 times in the last year
- Diagnosed or suspected interstitial cystitis
- Clinically significant bladder outlet obstruction or poor detrusor function defined by clinical symptoms and investigator's opinion according to local standard of care
- Previous history of major urethral and/or bladder surgery
- History of radiation treatment (external or interstitial) to pelvic organs or external genitalia for any reason.
- Subjects with neuropathology that could affect the lower urinary tract or nerve supply
- Patients with marked cystocele or other clinically significant pelvic prolapse.
- Subjects with current (within 2 years) urogenital neoplasms or malignancies including bladder, uterine or cervical cancer
- Treatment within the 14 days preceding randomization, or expected to initiate treatment during the study with: Any anticholinergic drugs other than trial drug Any drug treatment for overactive bladder
- On an unstable dosage of any drug with anticholinergic side effects, or expected to start such treatment during the study
- Subjects currently taking tricyclic antidepressants, diuretics or alpha blockers who have not been on a stable dose of these medications for at least one month
- Current administration of a selective serotonin reuptake inhibitor (SSRI) and has not been on a stable dose for at least three months
- Receipt of any electrostimulation or bladder training within the 14 days before randomization, or expected to start such treatment during the study
- An indwelling catheter or practicing intermittent self-catheterization
- Use of any investigational drug within 1 months preceding the start of the study
- Patients with chronic constipation or history of severe constipation
- Pregnant or nursing women
- Sexually active females of childbearing potential not using reliable contraception for at least 1 month prior to study start and not agreeing to use such methods during the entire study period and for at least 1 month thereafter \*Reliable contraceptive methods are defined as intrauterine devices (IUDs), combination type contraceptive pills, hormonal implants, double barrier method, injectable contraceptives and surgical procedures (tubal ligation or vasectomy).
- Any other condition which makes the patient unsuitable for inclusion.
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2012
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT00836381
Start Date
February 1 2009
End Date
January 1 2012
Last Update
May 30 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Samsung Medical Center
Seoul, South Korea